Manufacture of basic pharmaceutical products
SCANDIDERMA AS
Revenue 2024
NOK 1.3m
Operating profit
NOK 1.1m
Equity
NOK −6.0m
Incorporated
2010
Share capital
NOK 241,000
Financials
Total operating revenue
Operating profit (EBIT)
Income statement
| Post | 2024 | Trend |
|---|---|---|
| Total operating revenue | 1.3m | |
| Total operating costs | 162k | |
| Operating profit (EBIT) | 1.1m | |
| Net financial items | 114k | |
| Profit for the year | 1.2m |
Balance sheet
| Post | 2024 | Trend |
|---|---|---|
| Total assets | 416k | |
| of which current assets | 33k | |
| Equity | −6.0m | |
| Total liabilities | 6.4m |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.